Мирзатен

Основна информация

  • Търговско наименование:
  • Мирзатен 30 mg филмирани таблетки x 30 x 60 x 90
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Мирзатен 30 mg филмирани таблетки x 30 x 60 x 90
    България
  • Език:
  • български

Терапевтична информация

  • Каталог на резюме:
  • Mirzaten, 30 mg film-coated tablets x 30 x 60 x 90

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Номер на разрешението:
  • 20040227
  • Дата Оторизация:
  • 13-11-2015
  • Последна актуализация:
  • 01-06-2018

Листовка за пациента

21-9-2018

FDA Animal Drug Safety Communication: FDA Reminds Veterinarians of the Differences Between Approved and Compounded Formulas of Transdermal Mirtazapine for the Management of Weight Loss in Cats

FDA Animal Drug Safety Communication: FDA Reminds Veterinarians of the Differences Between Approved and Compounded Formulas of Transdermal Mirtazapine for the Management of Weight Loss in Cats

CVM Update describing FDA Dear Veterinarian Letter about the differences between FDA-approved Mirataz (mirtazapine transdermal ointment), an animal drug with demonstrated safety and effectiveness to manage undesired weight loss in cats, and compounded formulations of transdermal mirtazapine.

FDA - U.S. Food and Drug Administration

14-5-2018

FDA Approves Mirataz, a New Animal Drug to Manage Undesired Weight Loss in Cats

FDA Approves Mirataz, a New Animal Drug to Manage Undesired Weight Loss in Cats

FDA has approved Mirataz (mirtazapine transdermal ointment), a new animal drug to manage undesired weight loss in cats. Mirataz is the first transdermal product to receive FDA approval for use in cats. FDA-approved drugs have been demonstrated to be safe and effective for their intended use.

FDA - U.S. Food and Drug Administration

Няма новини за този продукт.